EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn’s Disease Patients: A Prospective Open-label Study

Geert D'Haens, Michael Eberhardson, Zeljko Cabrijan, Silvio Danese iD, Remco van den Berg, Mark Löwenberg, Gionata Fiorino iD, P Richard Schuurman, Göran Lind, Per Almqvist, Peder S Olofsson, Kevin J Tracey und 4 weitere

Journal of Crohn's and Colitis · 30.12.2023 · 17 (12) · 1897-1909

DOI: 10.1093/ecco-jcc/jjad151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Crohn's and Colitis, online erschienen am 21.09.2023. Verfasst von Geert D'Haens und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Crohn Disease, Vagus Nerve Stimulation, Biological Products. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SetPoint Medical, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Crohn’s disease [CD] is a debilitating, inflammatory condition affecting the gastrointestinal tract. There is no cure and sustained clinical and endoscopic remission is achieved by fewer than half of patients with current therapies. The immunoregulatory function of the vagus nerve, the ‘inflammatory reflex’, has been established in patients with rheumatoid arthritis and biologic-naive CD. The aim of this study was to explore the safety and efficacy of vagus nerve stimulation in patients with treatment-refractory CD, in a 16-week, open-label, multicentre, clinical trial.

Methods

A vagus nerve stimulator was implanted in 17 biologic drug-refractory patients with moderately to severely active CD. One patient exited the study pre-treatment, and 16 patients were treated with vagus nerve stimulation [4/16 receiving concomitant biologics] during 16 weeks of induction and 24 months of maintenance treatment. Endpoints included clinical improvement, patient-reported outcomes, objective measures of inflammation [endoscopic/molecular], and safety.

Results

There was a statistically significant and clinically meaningful decrease in CD Activity Index at Week 16 [mean ± SD: -86.2 ± 92.8, p = 0.003], a significant decrease in faecal calprotectin [-2923 ± 4104, p = 0.015], a decrease in mucosal inflammation in 11/15 patients with paired endoscopies [-2.1 ± 1.7, p = 0.23], and a decrease in serum tumour necrosis factor and interferon-γ [46–52%]. Two quality-of-life indices improved in 7/11 patients treated without biologics. There was one study-related severe adverse event: a postoperative infection requiring device explantation.

Conclusions

Neuroimmune modulation via vagus nerve stimulation was generally safe and well tolerated, with a clinically meaningful reduction in clinical disease activity associated with endoscopic improvement, reduced levels of faecal calprotectin and serum cytokines, and improved quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseVagus Nerve StimulationBiological ProductsHumansProspective StudiesQuality of LifeRemission InductionInflammationLeukocyte L1 Antigen Complex

Stichwörter der Autor:innen

Crohn’s diseaseneuroimmune modulationvagus nerve

Substanzen

Biological ProductsLeukocyte L1 Antigen Complex

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands.
  • Department of Medicine, Karolinska Institutet, Solna, Sweden.
  • Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
  • Division of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, Zagreb, Croatia.
  • Division of Gastroenterology, University of Applied Health Sciences, Zagreb, Croatia.
  • Josip Juraj Strossmayer University of Osijek School of Medicine, Osijek, Croatia.

ORCID-Profile: Silvio Danese, Gionata Fiorino, Yaakov A Levine

Förderung

  • SetPoint Medical, Inc

Zitieren

APA

D'Haens, G., Eberhardson, M., Cabrijan, Z., Danese, S., van den Berg, R., Löwenberg, M., Fiorino, G., Schuurman, P. R., Lind, G., Almqvist, P., Olofsson, P. S., Tracey, K. J., Hanauer, S. B., Zitnik, R., Chernoff, D., & Levine, Y. A. (2023). Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn’s Disease Patients: A Prospective Open-label Study. Journal of Crohn's and Colitis, 17(12), 1897-1909. https://doi.org/10.1093/ecco-jcc/jjad151

Vancouver

D'Haens G, Eberhardson M, Cabrijan Z, Danese S, van den Berg R, Löwenberg M, et al. Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn’s Disease Patients: A Prospective Open-label Study. Journal of Crohn's and Colitis. 2023;17(12):1897-1909. doi:10.1093/ecco-jcc/jjad151

BibTeX
@article{DHaens2023,
  author = {D'Haens, Geert and Eberhardson, Michael and Cabrijan, Zeljko and Danese, Silvio and van den Berg, Remco and Löwenberg, Mark and Fiorino, Gionata and Schuurman, P Richard and Lind, Göran and Almqvist, Per and Olofsson, Peder S and Tracey, Kevin J and Hanauer, Stephen B and Zitnik, Ralph and Chernoff, David and Levine, Yaakov A},
  title = {Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn’s Disease Patients: A Prospective Open-label Study},
  journal = {Journal of Crohn's and Colitis},
  year = {2023},
  volume = {17},
  number = {12},
  pages = {1897--1909},
  doi = {10.1093/ecco-jcc/jjad151}
}
Kostenlos starten →